Operaciones de insiders

EDGAR

Arcus Biosciences, Inc.

Operaciones informadas por directores, ejecutivos y titulares de más del 10 % en los Formularios 3, 4 y 5 de la SEC, leídas del XML de cada presentación. Los códigos y su redacción son los de la SEC.

El Formulario 4 debe presentarse dentro de los dos días hábiles posteriores a la operación, por lo que las más recientes pueden no estar presentadas aún.

Ventana: operaciones con fecha desde el 17 nov 2025.

Compras en el mercado abierto (código P)
0 operaciones, — acciones
Ventas en el mercado abierto (código S)
35 operaciones, 434.039 acciones
Suma de acciones × precio por acción: 10.472.021,3313

Los totales suman las operaciones presentadas que se listan; cuentan lo informado y no miden una dirección.

Mostrando 1–50 de 72

Operaciones de insiders, las más recientes primero, según los Formularios 3, 4 y 5 de la SEC
FechaTitular informanteCódigoAdquirido o enajenadoAccionesPrecio por acción, según lo presentadoValor (derivado)Acciones poseídas despuésDirecta o indirectaCasilla de la Regla 10b5-1NotasFuente
21 ago 2026 Presentado el 24 ago 2026Azoy Alexander Officer: Chief Accounting Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Adquirido (A)282715,44
43.648,88

Derivado: acciones × precio por acción. Valor exacto 43648.88.

42.408Directa (D) Sí
F1, F2
  • F1 The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
  • F2 Includes the unvested portion of the Reporting Person's RSU grants.
Abrir presentación 0001771961-26-000006 Leído del XML de la presentación Disputar esta fila
21 ago 2026 Presentado el 24 ago 2026Azoy Alexander Officer: Chief Accounting Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Enajenado (D)282730
84.810

Derivado: acciones × precio por acción. Valor exacto 84810.

39.581Directa (D) Sí
F1, F2
  • F1 The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
  • F2 Includes the unvested portion of the Reporting Person's RSU grants.
Abrir presentación 0001771961-26-000006 Leído del XML de la presentación Disputar esta fila
21 ago 2026 Presentado el 24 ago 2026Azoy Alexander Officer: Chief Accounting Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Valor derivado: Stock Option (right to buy) — subyacente Common Stock (2827) — precio de ejercicio 15.44
Enajenado (D)28270—3073Directa (D) Sí
F1, F3
  • F1 The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
  • F3 The option becomes exercisable in 48 equal monthly installments after January 1, 2024, subject to the Reporting Person's continued service to the Company.
Abrir presentación 0001771961-26-000006 Leído del XML de la presentación Disputar esta fila
10 jul 2026 Presentado el 13 jul 2026Jaen Juan C. Officer: President
S

Open market or private sale of non-derivative or derivative security

Common Stock
Enajenado (D)19.79928,608
566.409,792

Derivado: acciones × precio por acción. Valor exacto 566409.792.

822.508Indirecta (I) By TrustSí
F1, F3
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
  • F3 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.17 to $29.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Abrir presentación 0001422996-26-000006 Leído del XML de la presentación Disputar esta fila
10 jul 2026 Presentado el 13 jul 2026Jaen Juan C. Officer: President
S

Open market or private sale of non-derivative or derivative security

Common Stock
Enajenado (D)26829,397
7878,396

Derivado: acciones × precio por acción. Valor exacto 7878.396.

822.240Indirecta (I) By TrustSí
F1, F4
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
  • F4 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.30 to $29.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Abrir presentación 0001422996-26-000006 Leído del XML de la presentación Disputar esta fila
9 jul 2026 Presentado el 13 jul 2026Jaen Juan C. Officer: President
S

Open market or private sale of non-derivative or derivative security

Common Stock
Enajenado (D)48.50230,053
1.457.630,606

Derivado: acciones × precio por acción. Valor exacto 1457630.606.

842.307Indirecta (I) By TrustSí
F1, F2
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
  • F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.86 to $30.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Abrir presentación 0001422996-26-000006 Leído del XML de la presentación Disputar esta fila
24 jun 2026 Presentado el 24 jun 2026Jaen Juan C. Officer: President
S

Open market or private sale of non-derivative or derivative security

Common Stock
Enajenado (D)643129,6595
190.740,2445

Derivado: acciones × precio por acción. Valor exacto 190740.2445.

890.809Indirecta (I) By TrustSí
F1, F5
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.
  • F5 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.50 to $29.8050, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Abrir presentación 0001610717-26-000294 Leído del XML de la presentación Disputar esta fila
23 jun 2026 Presentado el 24 jun 2026Jaen Juan C. Officer: President
S

Open market or private sale of non-derivative or derivative security

Common Stock
Enajenado (D)14.06727,6875
389.480,0625

Derivado: acciones × precio por acción. Valor exacto 389480.0625.

898.937Indirecta (I) By TrustSí
F1, F3
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.
  • F3 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.01 to $28.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Abrir presentación 0001610717-26-000294 Leído del XML de la presentación Disputar esta fila
23 jun 2026 Presentado el 24 jun 2026Jaen Juan C. Officer: President
S

Open market or private sale of non-derivative or derivative security

Common Stock
Enajenado (D)169728,0612
47.619,8564

Derivado: acciones × precio por acción. Valor exacto 47619.8564.

897.240Indirecta (I) By TrustSí
F1, F4
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.
  • F4 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.0050 to $28.1550, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Abrir presentación 0001610717-26-000294 Leído del XML de la presentación Disputar esta fila
22 jun 2026 Presentado el 24 jun 2026Jaen Juan C. Officer: President
S

Open market or private sale of non-derivative or derivative security

Common Stock
Enajenado (D)923627,0313
249.661,0868

Derivado: acciones × precio por acción. Valor exacto 249661.0868.

913.004Indirecta (I) By TrustSí
F1, F2
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.
  • F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Abrir presentación 0001610717-26-000294 Leído del XML de la presentación Disputar esta fila
11 jun 2026 Presentado el 12 jun 2026Lacey David L. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)57000—76.652Directa (D) No
F1
  • F1 Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.
Abrir presentación 0001734422-26-000005 Leído del XML de la presentación Disputar esta fila
11 jun 2026 Presentado el 12 jun 2026Lacey David L. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor derivado: Stock Option (Right to Buy) — subyacente Stock Option (Rights to Buy) (16.900) — precio de ejercicio 23.30
Adquirido (A)16.9000—16.900Directa (D) No
F2
  • F2 The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.
Abrir presentación 0001734422-26-000005 Leído del XML de la presentación Disputar esta fila
11 jun 2026 Presentado el 12 jun 2026Machado Patrick Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)57000—44.300Directa (D) No
F1
  • F1 Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.
Abrir presentación 0001311210-26-000003 Leído del XML de la presentación Disputar esta fila
11 jun 2026 Presentado el 12 jun 2026Machado Patrick Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor derivado: Stock Option (Right to Buy) — subyacente Stock Option (Rights to Buy) (16.900) — precio de ejercicio 23.30
Adquirido (A)16.9000—16.900Directa (D) No
F2
  • F2 The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.
Abrir presentación 0001311210-26-000003 Leído del XML de la presentación Disputar esta fila
11 jun 2026 Presentado el 12 jun 2026Tang Carolyn C. Officer: General Counsel
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Adquirido (A)34.0902,574
87.747,66

Derivado: acciones × precio por acción. Valor exacto 87747.660.

184.607Directa (D) No
F1, F2
  • F1 Includes 1,783 shares purchased on May 31, 2026 through the Company's Employee Stock Purchase Plan.
  • F2 Includes the unvested portion of the Reporting Person's RSU grants.
Abrir presentación 0001836662-26-000005 Leído del XML de la presentación Disputar esta fila
11 jun 2026 Presentado el 12 jun 2026Tang Carolyn C. Officer: General Counsel
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Valor derivado: Stock Option (Right to Buy) — subyacente Common Stock (34.090) — precio de ejercicio 2.574
Enajenado (D)34.0902,574
87.747,66

Derivado: acciones × precio por acción. Valor exacto 87747.660.

0Directa (D) No
F3
  • F3 The option is fully vested and has been completely exercised.
Abrir presentación 0001836662-26-000005 Leído del XML de la presentación Disputar esta fila
11 jun 2026 Presentado el 12 jun 2026PERLMAN ANDREW J Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)57000—48.325Directa (D) No
F1
  • F1 Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.
Abrir presentación 0001201617-26-000003 Leído del XML de la presentación Disputar esta fila
11 jun 2026 Presentado el 12 jun 2026PERLMAN ANDREW J Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor derivado: Stock Option (Right to Buy) — subyacente Stock Option (Rights to Buy) (16.900) — precio de ejercicio 23.30
Adquirido (A)16.9000—16.900Directa (D) No
F2
  • F2 The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.
Abrir presentación 0001201617-26-000003 Leído del XML de la presentación Disputar esta fila
11 jun 2026 Presentado el 12 jun 2026FALBERG KATHRYN E Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)57000—44.300Directa (D) No
F1
  • F1 Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.
Abrir presentación 0001206977-26-000009 Leído del XML de la presentación Disputar esta fila
11 jun 2026 Presentado el 12 jun 2026FALBERG KATHRYN E Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor derivado: Stock Option (Right to Buy) — subyacente Stock Option (Rights to Buy) (16.900) — precio de ejercicio 23.30
Adquirido (A)16.9000—16.900Directa (D) No
F3
  • F3 The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.
Abrir presentación 0001206977-26-000009 Leído del XML de la presentación Disputar esta fila
11 jun 2026 Presentado el 12 jun 2026Ribas Antoni Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)57000—44.300Directa (D) No
F1
  • F1 Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.
Abrir presentación 0001792164-26-000006 Leído del XML de la presentación Disputar esta fila
11 jun 2026 Presentado el 12 jun 2026Ribas Antoni Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor derivado: Stock Option (Right to Buy) — subyacente Stock Option (Rights to Buy) (16.900) — precio de ejercicio 23.30
Adquirido (A)16.9000—16.900Directa (D) No
F2
  • F2 The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.
Abrir presentación 0001792164-26-000006 Leído del XML de la presentación Disputar esta fila
11 jun 2026 Presentado el 12 jun 2026Lambert Nicole Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)57000—43.000Directa (D) No
F1
  • F1 Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.
Abrir presentación 0001770252-26-000003 Leído del XML de la presentación Disputar esta fila
11 jun 2026 Presentado el 12 jun 2026Lambert Nicole Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor derivado: Stock Option (Right to Buy) — subyacente Stock Option (Rights to Buy) (16.900) — precio de ejercicio 23.30
Adquirido (A)16.9000—16.900Directa (D) No
F2
  • F2 The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.
Abrir presentación 0001770252-26-000003 Leído del XML de la presentación Disputar esta fila
11 jun 2026 Presentado el 12 jun 2026KANEKO YASUNORI Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)57000—25.700Directa (D) No
F1
  • F1 Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.
Abrir presentación 0001277503-26-000003 Leído del XML de la presentación Disputar esta fila
11 jun 2026 Presentado el 12 jun 2026KANEKO YASUNORI Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor derivado: Stock Option (Right to Buy) — subyacente Stock Option (Rights to Buy) (16.900) — precio de ejercicio 23.30
Adquirido (A)16.9000—16.900Directa (D) No
F3
  • F3 The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.
Abrir presentación 0001277503-26-000003 Leído del XML de la presentación Disputar esta fila
1 jun 2026 Presentado el 1 jun 2026Azoy Alexander Officer: Chief Accounting Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Enajenado (D)256225,7704
66.023,7648

Derivado: acciones × precio por acción. Valor exacto 66023.7648.

39.581Directa (D) Sí
F1, F2, F3, F4
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
  • F2 Consists of 2,562 shares purchased on 5/29/2026 through the Company's Employee Stock Purchase Plan.
  • F3 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.67 to $25.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  • F4 Includes the unvested portion of the Reporting Person's RSU grants.
Abrir presentación 0001771961-26-000004 Leído del XML de la presentación Disputar esta fila
11 may 2026 Presentado el 12 may 2026Goeltz II Robert C. Officer: Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Enajenado (D)776325,63
198.965,69

Derivado: acciones × precio por acción. Valor exacto 198965.69.

84.161Directa (D) Sí
F1, F2
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
  • F2 Includes the unvested portion of the reporting person's RSU grants.
Abrir presentación 0001653881-26-000005 Leído del XML de la presentación Disputar esta fila
23 ene 2026 Presentado el 26 ene 2026Markus Richard Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)24.0000—89.647Directa (D) No
F1, F2
  • F1 Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company.
  • F2 Includes the unvested portion of the Reporting Person's RSU grants.
Abrir presentación 0002056093-26-000002 Leído del XML de la presentación Disputar esta fila
23 ene 2026 Presentado el 26 ene 2026Markus Richard Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor derivado: Stock Option (right to buy) — subyacente Common Stock (96.000) — precio de ejercicio 22.13
Adquirido (A)96.0000—96.000Directa (D) No
F3
  • F3 The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company.
Abrir presentación 0002056093-26-000002 Leído del XML de la presentación Disputar esta fila
23 ene 2026 Presentado el 26 ene 2026Jaen Juan C. Officer: President
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)31.0000—377.012Directa (D) No
F1, F2
  • F1 Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company.
  • F2 Includes the unvested portion of the Reporting Person's RSU grants.
Abrir presentación 0001422996-26-000004 Leído del XML de la presentación Disputar esta fila
23 ene 2026 Presentado el 26 ene 2026Jaen Juan C. Officer: President
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor derivado: Stock Option (right to buy) — subyacente Common Stock (126.000) — precio de ejercicio 22.13
Adquirido (A)126.0000—126.000Directa (D) No
F3
  • F3 The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company.
Abrir presentación 0001422996-26-000004 Leído del XML de la presentación Disputar esta fila
23 ene 2026 Presentado el 26 ene 2026ROSEN TERRY J Director · Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)79.0000—2.236.409Directa (D) No
F1, F2
  • F1 Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company.
  • F2 Includes the unvested portion of the Reporting Person's RSU grants.
Abrir presentación 0001182473-26-000005 Leído del XML de la presentación Disputar esta fila
23 ene 2026 Presentado el 26 ene 2026ROSEN TERRY J Director · Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor derivado: Stock Option (right to buy) — subyacente Common Stock (315.000) — precio de ejercicio 22.13
Adquirido (A)315.0000—315.000Directa (D) No
F3
  • F3 The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company.
Abrir presentación 0001182473-26-000005 Leído del XML de la presentación Disputar esta fila
23 ene 2026 Presentado el 26 ene 2026Goeltz II Robert C. Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)24.0000—91.924Directa (D) No
F1, F2
  • F1 Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company.
  • F2 Includes the unvested portion of the Reporting Person's RSU grants.
Abrir presentación 0001653881-26-000002 Leído del XML de la presentación Disputar esta fila
23 ene 2026 Presentado el 26 ene 2026Goeltz II Robert C. Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor derivado: Stock Option (right to buy) — subyacente Common Stock (96.000) — precio de ejercicio 22.13
Adquirido (A)96.0000—96.000Directa (D) No
F3
  • F3 The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company.
Abrir presentación 0001653881-26-000002 Leído del XML de la presentación Disputar esta fila
23 ene 2026 Presentado el 26 ene 2026Azoy Alexander Officer: Chief Accounting Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)21.0500—39.581Directa (D) No
F1, F2
  • F1 Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company.
  • F2 Includes the unvested portion of the Reporting Person's RSU grants.
Abrir presentación 0001771961-26-000002 Leído del XML de la presentación Disputar esta fila
23 ene 2026 Presentado el 26 ene 2026Azoy Alexander Officer: Chief Accounting Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor derivado: Stock Option (right to buy) — subyacente Common Stock (14.050) — precio de ejercicio 22.13
Adquirido (A)14.0500—14.050Directa (D) No
F3
  • F3 The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company.
Abrir presentación 0001771961-26-000002 Leído del XML de la presentación Disputar esta fila
23 ene 2026 Presentado el 26 ene 2026Tang Carolyn C. Officer: General Counsel
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)24.0000—148.734Directa (D) No
F1, F2
  • F1 Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company.
  • F2 Includes the unvested portion of the Reporting Person's RSU grants.
Abrir presentación 0001836662-26-000002 Leído del XML de la presentación Disputar esta fila
23 ene 2026 Presentado el 26 ene 2026Tang Carolyn C. Officer: General Counsel
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor derivado: Stock Option (right to buy) — subyacente Common Stock (96.000) — precio de ejercicio 22.13
Adquirido (A)96.0000—96.000Directa (D) No
F3
  • F3 The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company.
Abrir presentación 0001836662-26-000002 Leído del XML de la presentación Disputar esta fila
23 ene 2026 Presentado el 26 ene 2026Jarrett Jennifer Officer: Chief Operating Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)31.0000—224.024Directa (D) No
F1, F2
  • F1 Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company.
  • F2 Includes the unvested portion of the Reporting Person's RSU grants.
Abrir presentación 0001671311-26-000002 Leído del XML de la presentación Disputar esta fila
23 ene 2026 Presentado el 26 ene 2026Jarrett Jennifer Officer: Chief Operating Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor derivado: Stock Option (right to buy) — subyacente Common Stock (126.000) — precio de ejercicio 22.13
Adquirido (A)126.0000—126.000Directa (D) No
F3
  • F3 The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company.
Abrir presentación 0001671311-26-000002 Leído del XML de la presentación Disputar esta fila
8 ene 2026 Presentado el 9 ene 2026ROSEN TERRY J Director · Officer: Chief Executive Officer
G

Bona fide gift

Common Stock
Enajenado (D)35.0000—2.157.409Directa (D) No
F1, F2
  • F1 Represents a charitable gift by the reporting person.
  • F2 Includes the unvested portion of the reporting person's RSU grants.
Abrir presentación 0001182473-26-000003 Leído del XML de la presentación Disputar esta fila
5 ene 2026 Presentado el 7 ene 2026Jaen Juan C. Officer: President
S

Open market or private sale of non-derivative or derivative security

Common Stock
Enajenado (D)29.67021,34
633.157,8

Derivado: acciones × precio por acción. Valor exacto 633157.80.

924.393Indirecta (I) By TrustSí
F1, F2
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2025.
  • F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.975 to $21.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Abrir presentación 0001422996-26-000002 Leído del XML de la presentación Disputar esta fila
5 ene 2026 Presentado el 7 ene 2026Jaen Juan C. Officer: President
S

Open market or private sale of non-derivative or derivative security

Common Stock
Enajenado (D)205322,34
45.864,02

Derivado: acciones × precio por acción. Valor exacto 45864.02.

922.340Indirecta (I) By TrustSí
F1, F3
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2025.
  • F3 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.04 to $22.985, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Abrir presentación 0001422996-26-000002 Leído del XML de la presentación Disputar esta fila
5 ene 2026 Presentado el 7 ene 2026Jaen Juan C. Officer: President
S

Open market or private sale of non-derivative or derivative security

Common Stock
Enajenado (D)10023,20
2320

Derivado: acciones × precio por acción. Valor exacto 2320.00.

922.240Indirecta (I) By TrustSí
F1
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2025.
Abrir presentación 0001422996-26-000002 Leído del XML de la presentación Disputar esta fila
31 dic 2025 Presentado el 2 ene 2026Goeltz II Robert C. Officer: Chief Financial Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Enajenado (D)655223,38
153.185,76

Derivado: acciones × precio por acción. Valor exacto 153185.76.

67.924Directa (D) Sí
F1
  • F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
Abrir presentación 0001610717-26-000002 Leído del XML de la presentación Disputar esta fila
30 dic 2025 Presentado el 2 ene 2026ROSEN TERRY J Director · Officer: Chief Executive Officer
G

Bona fide gift

Common Stock
Enajenado (D)24000—2.192.409Directa (D) No
F1
  • F1 2,400 shares were transferred to various family trusts in which the reporting person has no pecuniary interest, but retains voting and dispositive power over all of the shares transferred to each trust.
Abrir presentación 0001610717-26-000001 Leído del XML de la presentación Disputar esta fila
18 dic 2025 Presentado el 18 dic 2025Azoy Alexander Officer: Chief Accounting Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Enajenado (D)434322,2458
96.613,5094

Derivado: acciones × precio por acción. Valor exacto 96613.5094.

18.531Directa (D) Sí
F5, F6, F3
  • F5 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 6, 2025.
  • F6 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.90 to $22.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  • F3 Includes the unvested portion of the reporting person's RSU grants.
Abrir presentación 0001771961-25-000014 Leído del XML de la presentación Disputar esta fila
17 dic 2025 Presentado el 18 dic 2025Tang Carolyn C. Officer: General Counsel
S

Open market or private sale of non-derivative or derivative security

Common Stock
Enajenado (D)681022,1595
150.906,195

Derivado: acciones × precio por acción. Valor exacto 150906.1950.

124.734Directa (D) Sí
F1, F5, F4
  • F1 Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on May 22, 2025, and does not represent a discretionary trade by the reporting person.
  • F5 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.92 to $22.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  • F4 Includes the unvested portion of the reporting person's RSU grants.
Abrir presentación 0001836662-25-000005 Leído del XML de la presentación Disputar esta fila

Titulares institucionales (Formulario 13F)

Trimestre terminado el 2026-09-30: 7211 presentaciones leídas, la última del 13 nov 2026. Trimestre anterior terminado el 2026-06-30: 9150 presentaciones leídas.

Mostrando 1–50 de 180

Titulares institucionales, la posición mayor primero, según lo presentado
GestorAcciones o principalValor según lo presentadoDiferencia con el trimestre anteriorFuente
GILEAD SCIENCES, INC. 31.424.760 SH811.701.551 dólaresSin cambios Trimestre anterior: 31.424.760Abrir presentación 0001123292-26-001479 Presentado el 6 nov 2026 Disputar esta fila
BlackRock, Inc. Informado en parte bajo otro gestor16.824.688 SH434.581.690 dólaresMayor en 408.439 Trimestre anterior: 16.416.249Abrir presentación 0002012383-26-003985 Presentado el 13 nov 2026 Disputar esta fila
STATE STREET CORP Informado en parte bajo otro gestor5.570.292 SH143.880.642 dólaresMenor en 459.192 Trimestre anterior: 6.029.484Abrir presentación 0000093751-26-000747 Presentado el 12 nov 2026 Disputar esta fila
VANGUARD PORTFOLIO MANAGEMENT LLC 4.440.422 SH114.696.100 dólaresMenor en 35.106 Trimestre anterior: 4.475.528Abrir presentación 0002100121-26-001150 Presentado el 13 nov 2026 Disputar esta fila
FMR LLC Informado en parte bajo otro gestor4.436.585 SH114.596.976 dólaresMayor en 386.828 Trimestre anterior: 4.049.757Abrir presentación 0000315066-26-002964 Presentado el 10 nov 2026 Disputar esta fila
VANGUARD CAPITAL MANAGEMENT LLC 3.931.334 SH101.546.357 dólaresMayor en 42.988 Trimestre anterior: 3.888.346Abrir presentación 0002100119-26-001711 Presentado el 13 nov 2026 Disputar esta fila
GEODE CAPITAL MANAGEMENT, LLC Informado en parte bajo otro gestor2.480.755 SH64.088.874 dólaresMayor en 32.006 Trimestre anterior: 2.448.749Abrir presentación 0001214717-26-000012 Presentado el 6 nov 2026 Disputar esta fila
Siren, L.L.C. Informado en parte bajo otro gestor2.420.430 SH62.519.707 dólaresSin cambios Trimestre anterior: 2.420.430Abrir presentación 0002005245-26-000013 Presentado el 12 nov 2026 Disputar esta fila
Fisher Asset Management, LLC Informado en parte bajo otro gestor1.918.497 SH49.554.776 dólaresMenor en 220.899 Trimestre anterior: 2.139.396Abrir presentación 0000850529-26-000009 Presentado el 6 nov 2026 Disputar esta fila
DIMENSIONAL FUND ADVISORS LP Informado en parte bajo otro gestor1.390.719 SH35.921.229 dólaresMenor en 43.601 Trimestre anterior: 1.434.320Abrir presentación 0000354204-26-001096 Presentado el 4 nov 2026 Disputar esta fila
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Informado en parte bajo otro gestor1.243.573 SH32.121.490 dólaresMenor en 175.960 Trimestre anterior: 1.419.533Abrir presentación 0001520354-26-000046 Presentado el 13 nov 2026 Disputar esta fila
Invesco Ltd. Informado en parte bajo otro gestor1.184.953 SH30.607.337 dólaresMayor en 339.720 Trimestre anterior: 845.233Abrir presentación 0000914208-26-000462 Presentado el 12 nov 2026 Disputar esta fila
MORGAN STANLEY Informado en parte bajo otro gestor1.165.831 SH30.113.437 dólaresMayor en 369.919 Trimestre anterior: 795.912Abrir presentación 0000895421-26-000309 Presentado el 13 nov 2026 Disputar esta fila
Aberdeen Group plc Informado en parte bajo otro gestor1.056.679 SH27.294.019 dólaresMayor en 405.967 Trimestre anterior: 650.712Abrir presentación 0001716774-26-000032 Presentado el 10 nov 2026 Disputar esta fila
JPMORGAN CHASE CO Informado en parte bajo otro gestor765.041 SH19.744.908 dólaresMayor en 346.798 Trimestre anterior: 418.243Abrir presentación 0000019617-26-000404 Presentado el 12 nov 2026 Disputar esta fila
LOOMIS SAYLES CO L P Informado en parte bajo otro gestor741.283 SH19.147.340 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0000312348-26-000039 Presentado el 12 nov 2026 Disputar esta fila
UBS Group AG Informado en parte bajo otro gestor665.892 SH17.199.990 dólaresMayor en 296.836 Trimestre anterior: 369.056Abrir presentación 0001610520-26-000121 Presentado el 10 nov 2026 Disputar esta fila
VANGUARD FIDUCIARY TRUST CO 633.133 SH16.353.825 dólaresMayor en 17.045 Trimestre anterior: 616.088Abrir presentación 0000933478-26-000017 Presentado el 13 nov 2026 Disputar esta fila
Bank of New York Mellon Corp Informado en parte bajo otro gestor544.259 SH14.058.221 dólaresMayor en 1250 Trimestre anterior: 543.009Abrir presentación 0001390777-26-000121 Presentado el 5 nov 2026 Disputar esta fila
Candriam S.C.A. 536.823 SH13.916.800 dólaresMenor en 125.158 Trimestre anterior: 661.981Abrir presentación 0001537014-26-000009 Presentado el 3 nov 2026 Disputar esta fila
PANAGORA ASSET MANAGEMENT INC 467.340 SH12.071.392 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0000883677-26-000011 Presentado el 12 nov 2026 Disputar esta fila
FIRST TRUST ADVISORS LP 460.504 SH11.894.818 dólaresMayor en 189.070 Trimestre anterior: 271.434Abrir presentación 0001445546-26-008622 Presentado el 12 nov 2026 Disputar esta fila
PRINCIPAL FINANCIAL GROUP INC Informado en parte bajo otro gestor439.195 SH11.344.408 dólaresMayor en 15.829 Trimestre anterior: 423.366Abrir presentación 0001126328-26-000225 Presentado el 2 nov 2026 Disputar esta fila
Decheng Capital LLC 425.079 SH10.979.791 dólaresMenor en 39.700 Trimestre anterior: 464.779Abrir presentación 0001104659-26-127247 Presentado el 13 nov 2026 Disputar esta fila
Patient Square Capital LP 410.000 SH10.590.300 dólaresMayor en 54.200 Trimestre anterior: 355.800Abrir presentación 0001819257-26-000007 Presentado el 10 nov 2026 Disputar esta fila
Public Sector Pension Investment Board 307.471 SH7.004.189 dólaresMayor en 9315 Trimestre anterior: 298.156Abrir presentación 0001396318-26-000039 Presentado el 10 nov 2026 Disputar esta fila
MARSHALL WACE, LLP Informado en parte bajo otro gestor278.263 SH7.187.533 dólaresMenor en 1.666.825 Trimestre anterior: 1.945.088Abrir presentación 0001318757-26-000012 Presentado el 13 nov 2026 Disputar esta fila
Jump Financial, LLC Informado en parte bajo otro gestor242.258 SH6.257.524 dólaresMayor en 160.222 Trimestre anterior: 82.036Abrir presentación 0000905148-26-004786 Presentado el 13 nov 2026 Disputar esta fila
Nuveen, LLC Informado en parte bajo otro gestor233.051 SH6.019.707 dólaresMenor en 1001 Trimestre anterior: 234.052Abrir presentación 0000930413-26-003284 Presentado el 10 nov 2026 Disputar esta fila
RHUMBLINE ADVISERS 232.631 SH6.008.826 dólaresMayor en 13.450 Trimestre anterior: 219.181Abrir presentación 0001115418-26-000015 Presentado el 10 nov 2026 Disputar esta fila
Hudson Bay Capital Management LP 230.000 SH5.940.900 dólaresMayor en 90.000 Trimestre anterior: 140.000Abrir presentación 0001393825-26-000083 Presentado el 13 nov 2026 Disputar esta fila
Ensign Peak Advisors, Inc 185.462 SH4.790.483 dólaresMenor en 30.151 Trimestre anterior: 215.613Abrir presentación 0001454984-26-000011 Presentado el 12 nov 2026 Disputar esta fila
Swiss National Bank 165.296 SH4.269.596 dólaresMenor en 10.800 Trimestre anterior: 176.096Abrir presentación 0001582202-26-000008 Presentado el 12 nov 2026 Disputar esta fila
Russell Investments Group, Ltd. Informado en parte bajo otro gestor134.530 SH3.474.926 dólaresMayor en 52.981 Trimestre anterior: 81.549Abrir presentación 0001193125-26-451241 Presentado el 6 nov 2026 Disputar esta fila
SECTORAL ASSET MANAGEMENT INC 115.933 SH2.994.549 dólaresMayor en 5063 Trimestre anterior: 110.870Abrir presentación 0001104659-26-126613 Presentado el 13 nov 2026 Disputar esta fila
BNP PARIBAS FINANCIAL MARKETS Informado en parte bajo otro gestor104.040 SH2.687.353 dólaresMenor en 49.069 Trimestre anterior: 153.109Abrir presentación 0001166588-26-000012 Presentado el 12 nov 2026 Disputar esta fila
RENAISSANCE TECHNOLOGIES LLC Informado en parte bajo otro gestor102.500 SH2.647.575 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0001037389-26-000062 Presentado el 12 nov 2026 Disputar esta fila
Knott David M Jr Informado en parte bajo otro gestor100.241 SH2.589.225 dólaresMayor en 19.000 Trimestre anterior: 81.241Abrir presentación 0001104659-26-125757 Presentado el 12 nov 2026 Disputar esta fila
NEW YORK STATE TEACHERS RETIREMENT SYSTEM 92.631 SH2393 dólaresMayor en 200 Trimestre anterior: 92.431Abrir presentación 0000314969-26-000011 Presentado el 22 oct 2026 Disputar esta fila
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 90.746 SH2.343.969 dólaresMenor en 6664 Trimestre anterior: 97.410Abrir presentación 0001081019-26-000023 Presentado el 13 nov 2026 Disputar esta fila
Rafferty Asset Management, LLC 89.897 SH2.322.040 dólaresMayor en 18.172 Trimestre anterior: 71.725Abrir presentación 0001999371-26-025241 Presentado el 13 nov 2026 Disputar esta fila
TEMA ETFS LLC 88.847 SH2.294.918 dólaresMayor en 5707 Trimestre anterior: 83.140Abrir presentación 0001829126-26-011223 Presentado el 16 oct 2026 Disputar esta fila
Tidal Investments LLC 88.847 SH2.294.918 dólaresMayor en 3721 Trimestre anterior: 85.126Abrir presentación 0002000324-26-006122 Presentado el 13 nov 2026 Disputar esta fila
DEUTSCHE BANK AG\ Informado en parte bajo otro gestor87.122 SH2.250.361 dólaresMenor en 7588 Trimestre anterior: 94.710Abrir presentación 0000948046-26-000083 Presentado el 6 nov 2026 Disputar esta fila
FOX RUN MANAGEMENT, L.L.C. 86.685 SH2.239.074 dólaresNo figura en las presentaciones leídas del trimestre anterior Abrir presentación 0001420506-26-002585 Presentado el 12 nov 2026 Disputar esta fila
Parallel Advisors, LLC 86.557 SH2.235.767 dólaresSin cambios Trimestre anterior: 86.557Abrir presentación 0001690010-26-000007 Presentado el 3 nov 2026 Disputar esta fila
BARCLAYS PLC Informado en parte bajo otro gestor85.064 SH2.197.204 dólaresMayor en 65.746 Trimestre anterior: 19.318Abrir presentación 0000312069-26-000241 Presentado el 6 nov 2026 Disputar esta fila
Connor, Clark Lunn Investment Management Ltd. 82.803 SH2.138.801 dólaresMenor en 142.205 Trimestre anterior: 225.008Abrir presentación 0001596800-26-000018 Presentado el 10 nov 2026 Disputar esta fila
Quantinno Capital Management LP 76.319 SH1.971.320 dólaresMayor en 19.064 Trimestre anterior: 57.255Abrir presentación 0001759654-26-000011 Presentado el 13 nov 2026 Disputar esta fila
CANADA LIFE ASSURANCE Co 70.518 SH1822 dólaresSin cambios Trimestre anterior: 70.518Abrir presentación 0001046192-26-000015 Presentado el 13 nov 2026 Disputar esta fila
Gestores del trimestre anterior sin presentación leída para el último

Quizá simplemente no hayan presentado aún: estar ausente de las presentaciones leídas del último trimestre no equivale a una posición vendida.

  • WELLINGTON MANAGEMENT GROUP LLP 5.895.448 SH
  • MONTANOVA CAPITAL, LLC 4.776.423 SH
  • CITADEL ADVISORS LLC 3.135.057 SH
  • Woodline Partners LP 3.007.798 SH
  • SAMLYN CAPITAL, LLC 1.547.182 SH
  • GOLDMAN SACHS GROUP INC 1.387.566 SH
  • Soleus Capital Management, L.P. 1.168.738 SH
  • Sofinnova Investments, Inc. 945.690 SH
  • Sixth Street Partners Management Company, L.P. 941.756 SH
  • CHARLES SCHWAB INVESTMENT MANAGEMENT INC 941.756 SH
  • NORTHERN TRUST CORP 932.523 SH
  • Parkman Healthcare Partners LLC 919.266 SH
  • BAKER BROS. ADVISORS LP 844.816 SH
  • BANK OF AMERICA CORP /DE/ 835.504 SH
  • Logos Global Management LP 650.000 SH
  • TWO SIGMA INVESTMENTS, LP 635.404 SH
  • T. Rowe Price Investment Management, Inc. 589.546 SH
  • JACOBS LEVY EQUITY MANAGEMENT, INC 512.084 SH
  • Ikarian Capital, LLC 504.559 SH
  • DAFNA Capital Management LLC 441.829 SH
  • NOMURA ASSET MANAGEMENT INTERNATIONAL INC. 379.100 SH
  • PDT Partners, LLC 323.567 SH
  • DIADEMA PARTNERS LP 223.810 SH
  • SUSQUEHANNA INTERNATIONAL GROUP, LLP 194.000 SH
  • Legal General Group Plc 191.560 SH
  • Rock Springs Capital Management LP 180.000 SH
  • UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC 154.398 SH
  • BOOTHBAY FUND MANAGEMENT, LLC 154.264 SH
  • AMERIPRISE FINANCIAL INC 153.813 SH
  • PFM Health Sciences, LP 152.129 SH
  • Man Group plc 137.763 SH
  • PLATINUM INVESTMENT MANAGEMENT LTD 134.217 SH
  • MILLENNIUM MANAGEMENT LLC 133.110 SH
  • ALLIANCEBERNSTEIN L.P. 126.975 SH
  • DIADEMA PARTNERS LP 124.000 SH
  • Schonfeld Strategic Advisors LLC 122.574 SH
  • PRUDENTIAL FINANCIAL INC 110.603 SH
  • D. E. Shaw Co., Inc. 96.417 SH
  • PRICE T ROWE ASSOCIATES INC /MD/ 89.202 SH
  • Odyssean, LLC 85.497 SH
  • AQR CAPITAL MANAGEMENT LLC 83.861 SH
  • WELLS FARGO COMPANY/MN 82.913 SH
  • Allianz Asset Management GmbH 82.458 SH
  • STATE OF WISCONSIN INVESTMENT BOARD 82.399 SH
  • Caption Management, LLC 62.000 SH
  • FRED ALGER MANAGEMENT, LLC 60.494 SH
  • BIT Capital GmbH 60.000 SH
  • Corient Private Wealth LP 59.127 SH
  • Susquehanna Portfolio Strategies, LLC 53.668 SH
  • MetLife Investment Management, LLC 52.110 SH
  • El Formulario 13F cubre solo posiciones largas en valores de la Sección 13(f): ni posiciones cortas ni valores fuera de esa lista.
  • Un gestor que aún no ha presentado el último trimestre está ausente, no en cero; las presentaciones vencen hasta 45 días después del cierre del trimestre.
  • Una diferencia es la que hay entre dos instantáneas de cierre de trimestre, no una operación.
  • Una posición informada bajo otro gestor puede aparecer también en la presentación de ese gestor; las filas no se suman.
  • No se muestran las posiciones que la lista de valores no puede atribuir a esta empresa o atribuye de forma ambigua.

Titulares del 5 % (Anexos 13D y 13G)

Aquí se leen los anexos presentados en el formato estructurado de la SEC (desde finales de 2024). Los anteriores son texto libre y no se leen.

Titulares del 5 %, el evento más reciente primero, según lo presentado
TitularPorcentaje de la claseAcciones en poderFecha del eventoFormularioFuente
Gilead Sciences, Inc. Common Stock, par value $0.000124.731.424.760,0008/05/2026 Presentado el 7 ago 2026SCHEDULE 13D/AEnmienda 7Abrir presentación 0001104659-26-092737 Disputar esta fila
The Vanguard Group Common Stock0003/13/2026 Presentado el 26 mar 2026SCHEDULE 13G/AEnmienda 2Abrir presentación 0000102909-26-000680 Disputar esta fila
BlackRock, Inc. Common Stock10.412.736.92712/31/2025 Presentado el 8 ene 2026SCHEDULE 13G/AEnmienda 6Abrir presentación 0002012383-26-000038 Disputar esta fila
GILEAD SCIENCES, INC. Common Stock, par value $0.000125.631.424.76011/03/2025 Presentado el 5 nov 2025SCHEDULE 13D/AEnmienda 6Abrir presentación 0001123292-25-000613 Disputar esta fila
Point72 Asset Management, L.P. Common Stock, par value $0.0001 per share4.14.332.479,0009/30/2025 Presentado el 14 nov 2025SCHEDULE 13G/AEnmienda 1Abrir presentación 0000902664-25-005004 Disputar esta fila
Point72 Capital Advisors, Inc. Common Stock, par value $0.0001 per share4.14.332.479,0009/30/2025 Presentado el 14 nov 2025SCHEDULE 13G/AEnmienda 1Abrir presentación 0000902664-25-005004 Disputar esta fila
Steven A. Cohen Common Stock, par value $0.0001 per share4.14.332.479,0009/30/2025 Presentado el 14 nov 2025SCHEDULE 13G/AEnmienda 1Abrir presentación 0000902664-25-005004 Disputar esta fila
GILEAD SCIENCES, INC. Common Stock, par value $0.000129.731.424.76007/13/2025 Presentado el 15 jul 2025SCHEDULE 13D/AEnmienda 5Abrir presentación 0001123292-25-000309 Disputar esta fila

El porcentaje es de la clase que indica la presentación, según lo declaró el titular. Los miembros de un grupo informan cada uno las acciones del grupo, por lo que las filas no se suman.

Qué se leyó

2.119.757 presentaciones leídas, del 14 jun 2004 al 13 nov 2026: Formularios 3, 3/A, 4, 4/A, 5, 5/A.

Algunos años pueden estar incompletos mientras se sigue leyendo el archivo. Un año con pocas presentaciones aquí no afirma que se hicieran pocas.

Presentaciones leídas, por año de presentación
Año de presentaciónPresentaciones leídas
20151
2016204.322
2017202.494
2018202.048
2019193.638
2020144.184
2021224.474
202242.927
2023199.811
2024209.823
2025235.520
2026254.737

Las presentaciones anteriores a que la SEC exigiera XML se listan, pero no se extraen.

Volver a Arcus Biosciences, Inc.